A carregar...
The genetic landscape of programmed death ligand‐1 (PD‐L1) alterations in head and neck cancer
OBJECTIVES: Nivolumab has recently been shown in the phase III clinical trial CheckMate‐141 to have superior survival rates compared to the current standard of care chemotherapy for recurrent or metastatic platinum‐resistant head and neck squamous cell carcinoma (HNSCC). Nivolumab targets the immune...
Na minha lista:
| Publicado no: | Laryngoscope Investig Otolaryngol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527359/ https://ncbi.nlm.nih.gov/pubmed/28894827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/lio2.79 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|